Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) was the recipient of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totalling 8,080,000 shares, a decrease of 5.8% from the July 15th total of 8,580,000 shares. Based on an average trading volume of 823,100 shares, the short-interest ratio is currently 9.8 days. Approximately 13.6% of the company’s shares are short sold.
Analysts Set New Price Targets
Several research firms have issued reports on EWTX. Royal Bank of Canada reissued an “outperform” rating and set a $32.00 target price on shares of Edgewise Therapeutics in a research note on Thursday, July 25th. Wedbush reissued an “outperform” rating and set a $31.00 price objective on shares of Edgewise Therapeutics in a research report on Friday, August 16th. JPMorgan Chase & Co. upped their target price on shares of Edgewise Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, August 12th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $48.00 target price on shares of Edgewise Therapeutics in a research note on Monday, July 1st. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $33.40.
View Our Latest Report on EWTX
Institutional Investors Weigh In On Edgewise Therapeutics
Edgewise Therapeutics Trading Up 4.8 %
EWTX stock opened at $19.72 on Wednesday. The business’s fifty day moving average price is $18.64 and its 200 day moving average price is $17.89. Edgewise Therapeutics has a 12-month low of $5.12 and a 12-month high of $23.50. The company has a market capitalization of $1.84 billion, a PE ratio of -12.72 and a beta of 0.14.
Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.02. Research analysts predict that Edgewise Therapeutics will post -1.59 EPS for the current fiscal year.
Edgewise Therapeutics Company Profile
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Read More
- Five stocks we like better than Edgewise Therapeutics
- How to Effectively Use the MarketBeat Ratings Screener
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- Canada Bond Market Holiday: How to Invest and Trade
- Lowe’s Stock: Hold Now, Buy it When it Dips
- What Are the U.K. Market Holidays? How to Invest and Trade
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.